Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.

Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E.

J Clin Psychopharmacol. 2002 Aug;22(4):419-23.

PMID:
12172343
2.

Plasma risperidone concentrations during combined treatment with sertraline.

Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A.

Ther Drug Monit. 2004 Aug;26(4):386-90.

PMID:
15257068
3.

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.

Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia A.

Ther Drug Monit. 2001 Jun;23(3):223-7.

PMID:
11360029
4.

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.

Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY.

Clin Pharmacol Ther. 2005 Nov;78(5):520-8. Epub 2005 Sep 26.

PMID:
16321618
5.

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E.

Psychopharmacology (Berl). 2001 Jan 1;153(2):238-43.

PMID:
11205425
6.

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML.

Psychopharmacology (Berl). 1999 Dec;147(3):300-5.

PMID:
10639689
7.

Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.

Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y, De Vries R, Kaneko S.

J Clin Pharmacol. 2002 Oct;42(10):1083-8.

PMID:
12362921
8.

Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.

Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T.

J Clin Pharmacol. 2003 Feb;43(2):122-7.

PMID:
12616663
9.

No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.

Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A.

Ther Drug Monit. 2001 Dec;23(6):675-8.

PMID:
11802103
10.

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.

Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E.

Ther Drug Monit. 2000 Aug;22(4):481-5.

PMID:
10942191
11.

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

Spina E, Avenoso A, Facciolà G, Fabrazzo M, Monteleone P, Maj M, Perucca E, Caputi AP.

Int Clin Psychopharmacol. 1998 May;13(3):141-5.

PMID:
9690983
12.

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, Kim YK, Kim SH, Han C, Lee MS, Park JY.

J Clin Psychopharmacol. 2009 Jun;29(3):272-7. doi: 10.1097/JCP.0b013e3181a289e0.

PMID:
19440082
13.

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.

Berecz R, LLerena A, de la Rubia A, Gómez J, Kellermann M, Dorado P, Degrell I.

Pharmacopsychiatry. 2002 Nov;35(6):231-4.

PMID:
12518271
14.

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.

Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L.

Eur J Clin Pharmacol. 2001 Nov;57(9):671-5.

PMID:
11791898
15.

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP.

Ther Drug Monit. 1999 Feb;21(1):105-15.

PMID:
10051063
16.

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L.

J Psychopharmacol. 2007 Nov;21(8):837-42. Epub 2007 Aug 22.

PMID:
17715206
17.

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J.

Int Clin Psychopharmacol. 2005 Mar;20(2):71-8.

PMID:
15729081
18.

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.

Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P.

Pharmacopsychiatry. 2002 Mar;35(2):50-6.

PMID:
11985287
19.

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.

Mannheimer B, von Bahr C, Pettersson H, Eliasson E.

Ther Drug Monit. 2008 Oct;30(5):565-9. doi: 10.1097/FTD.0b013e31818679c9.

PMID:
18728628
20.

Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.

Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, de Vries R, Kaneko S.

Psychopharmacology (Berl). 2002 Jun;162(1):50-4. Epub 2002 Apr 20.

PMID:
12107617

Supplemental Content

Support Center